On February 3, 2023, the U.S. Food and Drug Administration approved sacituzumab govitecan-hziy (Trodelvy®) for unresectable locally advanced or metastatic hormone receptor–positive, human epidermal growth factor receptor 2–negative (IHC 0, IHC 1+, or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.
To uncover what you value and whether your ONS membership is currently meeting your needs, ONS surveys its members every January. Your responses help us understand how you experience ONS and what is important to you as well as the challenges you face and the skills you need for the future. This year, 1,068 of you returned your surveys, and I am grateful that you took the time to provide your feedback.
Maria is a Black nurse who has worked at her institution’s cancer center for several years. She enjoys educating her colleagues about burnout and well-being to create a happier and healthier work environment and actively supports the institution’s diversity, equity, and inclusion (DEI) committee priorities and Black, Indigenous, and people of color (BIPOC) nurses in practice.
People encounter significant changes after being diagnosed with cancer. Oncology nurses can help patients and caregivers adapt by using motivational interviewing–based communication strategies.
Healthcare providers are less likely to talk to Black patients with metastatic breast cancer about opportunities to enroll in clinical trials than they are with patients from other racial or ethnic backgrounds, researchers reported at the 2022 ASCO Annual Meeting.
On January 27, 2023, the U.S. Food and Drug Administration approved elacestrant (Orserdu®) for postmenopausal women or adult men with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-variant advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
Oncology nurses recognize the value of mentorship in their practice, crediting it to bridging knowledge gaps, identifying best practices, building confidence, and providing a rock and safe person to go to. January is National Mentoring Month, and we’ve asked ONS members to share their own experiences that have helped them grow professionally and personally.
On January 26, 2023 the U.S. Food and Drug Administration removed its emergency use authorization of tixagevimab/cilgavimab (Evushield) for the prevention of SARS-CoV-2 infection after exposure to the virus. FDA said it made the decision because the agent is not effective in preventing infections from the current variants that are responsible for 90% of today’s infections and because the risks of the drug’s side effects do not outweigh the benefits.
On January 26, 2023, the U.S. Food and Drug Administration approved pembrolizumab (Keytruda®) for adjuvant treatment following resection and platinum-based chemotherapy of patients with stage IB (T2a ≥ 4 cm), II, or IIIA non-small cell lung cancer.
On January 27, 2023, the U.S. Food and Drug Administration granted accelerated approval to pirtobrutinib (Jaypirca®) for relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase inhibitor.